/
IMTX
$9.56+$0.04 (+0.42%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.3B
137M shares
52-week range
$5.05 – $12.41
61% from low
Exchange
NASDAQ
CS
Borrow rate
0.31%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-2.05
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.8M | $18.4M | $31.3M | $34.8M | $172.8M | $54.0M | $155.8M | $48.3M |
| Cost of revenue | $34.0M | $40.1M | $67.1M | $87.6M | $106.8M | $118.7M | $0 | $0 |
| Gross profit | −$30.2M | −$21.6M | −$35.8M | −$52.8M | $66.1M | −$64.7M | $155.8M | $48.3M |
| Gross margin | -801.1% | -117.3% | -114.7% | -151.9% | 38.2% | -119.8% | 100.0% | 100.0% |
| R&D | $34.0M | $40.1M | $67.1M | $87.6M | $106.8M | $118.7M | $148.1M | $183.8M |
| Operating income | −$34.4M | −$33.0M | −$69.7M | −$86.3M | $30.0M | −$101.7M | −$38.6M | −$182.0M |
| EBITDA | −$31.7M | −$28.5M | −$207.4M | −$87.3M | $50.0M | −$88.9M | $34.5M | −$185.1M |
| Net income | −$31.4M | −$31.7M | −$229.3M | −$95.1M | $37.5M | −$97.0M | $15.2M | −$196.4M |
| Net margin | -834.1% | -172.0% | -733.8% | -273.5% | 21.7% | -179.6% | 9.8% | -407.0% |
| EPS (diluted) | -0.50 | -0.50 | -4.78 | -1.51 | 0.54 | -1.20 | 0.14 | -1.54 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $43M | $-1.94 | $-2.73–$-1.23 | 7 |
| 2027 | $48M | $-1.90 | $-2.50–$-1.30 | 6 |
| 2028 | $112M | $-1.70 | $-1.87–$-1.39 | 4 |
| 2029 | $240M | $-1.16 | $-1.63–$-0.61 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Immatics N.V. Ordinary Shares
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
www.immatics.com- Employees
- 407
- IPO / List date
- Jul 2, 2020
Held by traders on TradeandTell
No one on the platform currently holds IMTX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in IMTX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IMTX yet.
